https://orcid.org/0000-0002-6472-6658
References
- Hasenclever D, Diehl V. A prognostic score for advanced hodgkin's disease. International prognostic factors project on advanced hodgkin's disease. N Engl J Med. 1998;339(21):1506–1514.
- Liu WR, Shipp MA. Signaling pathways and immune evasion mechanisms in classical hodgkin lymphoma. Blood. 2017;130(21):2265–2270.
- Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory hodgkin's lymphoma. N Engl J Med. 2015;372(4):311–319.
- Karakatsanis S. e. Serum ferritin levels in previously untreated classical hodgkin lymphoma: Correlations and prognostic significance. Leuk Lymphoma. 2022. [Note: this reference relates to the article from the current issue of Leukemia & Lymphoma - to be replaced when details are known].
- Casasnovas RO, Mounier N, Brice P, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical hodgkin's lymphoma: a study from the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol. 2007;25(13):1732–1740.
- Rautert R, Schinkothe T, Franklin J, et al. Elevated pretreatment interleukin-10 serum level is an international prognostic score (IPS)-independent risk factor for early treatment failure in advanced stage hodgkin lymphoma. Leuk Lymphoma. 2008;49(11):2091–2098.
- Hsi ED, Li H, Nixon AB, et al. Serum levels of TARC, MDC, IL-10, and soluble CD163 in hodgkin lymphoma: a SWOG S0816 correlative study. Blood. 2019;133(16):1762–1765.
- Marri PR, Hodge LS, Maurer MJ, et al. Prognostic significance of pretreatment serum cytokines in classical hodgkin lymphoma. Clin Cancer Res. 2013;19(24):6812–6819.
- Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical hodgkin lymphoma. Blood. 2018;131(22):2413–2425.
- Cader FZ, Hu X, Goh WL, et al. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical hodgkin lymphoma. Nat Med. 2020;26(9):1468–1479.